Peripheral T-cell lymphomas (PTCLs) are a biologically diverse and uncommon group of
diseases. Compared to their B-cell counterparts, PTCLs remain largely unexplored and the
optimal treatment ill-defined due to disease rarity and biological heterogeneity. With the
notable exception of ALK-pos anaplastic large cell lymphoma (ALCL), the prognosis of most
PTCL subtypes is extremely is poor with a 5 y overall survival of approximately 15-30% in
most series. The international prognostic index has been useful in defining different risk …